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Abstract 
 
Multimodality medical imaging offers a key role in disease diagnosis, while providing 
accurate staging and defining disease extent in many instances. Recent developments 
are increasingly leading to quantitative assessment of medical images, allowing both 
definition of disease extent, giving insight into the phenotypes of diseases and 
offering capabilities of monitoring response to therapy. Combined with other tools, 
such as genetic profiling, this is a powerful way of improving diagnosis and treatment 
of patients, enabling a personalised approach to delivering healthcare. It is highly 
likely that software tools will become integrated into the routine workflow of 
radiology reports. This special report describes some of the crucial areas where 
applications are being introduced and speculate on the potential impact on radiologists 
and clinicians. 
 
Keywords: Radiology, Imaging, Biomarkers, Computed Tomography, Magnetic 
Resonance Imaging, Positron Emission Tomography, Therapy Assessment, 
Quantification, Emphysema, Aortic Valve Stenosis 
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Background of imaging biomarkers 
 
Radiologic imaging has made a huge impact in the overall management of patients, 
allowing rapid and accurate diagnosis for many diseases in one way or another. The 
range of imaging includes anything from ultrasound to plain film radiography and 
more complex procedures with or without the need for ionising radiation. However, in 
spite of using imaging as a diagnostic test, it takes more work to develop an imaging-
based biomarker. 
 
An imaging biomarker is a biologic feature or characteristic, that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic 
processes or biological responses to a therapeutic intervention, detectable in an 
image.[1,2] In medicine, an imaging biomarker is a feature of an image relevant to a 
patient's diagnosis. As such, it has been postulated that imaging biomarkers can be 
used as a surrogate to predict outcome and to monitor disease response, thus replacing 
traditional methods such as clinical outcomes (e.g. recurrent disease or death). 
Surrogate biomarkers are thought to assess treatment effects more quickly, thus 
enabling more rapid determination and potential to change patient management.  
 
Although this all sounds relatively new, imaging has been used for many decades as 
an aid to diagnosis, to evaluate extent of disease and to help demonstrate efficacy of 
treatment. Initially this was done using plain radiography methods, and even today 
plain radiographs are commonly used for assessment and classification of spinal and 
other fractures and for follow-up of known lung nodules for instance. With  the 
advent of advanced imaging methods, such as Computed Tomography (CT), 
Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET), there 
is now increasing clarity in images that enable quantification in real terms, which in 
turn allows for more precise diagnosis and assessment. This is a key component to the 
planning of “Precision Medicine”, as  improving the phenotype description in the 
context of genetic testing is a very powerful method to indicate likely success of 
newly developed molecular targeted treatments. Thus, it becomes possible to relate 
images to anything from normal biological patterns up to pathophysiological findings 
and measurements of treatment effectiveness. Good examples of this type of imaging 
biomarker are the assessment of chemotherapy effects in cancer treatment (RECIST 
criteria) [3] and also the PET response in patients following treatment of head-neck 
cancer [4] and staging and therapy assessment of lymphoma [5]. 
 
Summary of the main advanced imaging methods 
Computed tomography (CT) is a method of ionising radiation transmission and 
measures density differences of the tissues. The method allows for a three-
dimensional assessment of the targeted volume of the body, and displays are now 
used which depict isovolumetric volumes of tissue (voxel), which can be probed in all 
three dimensions. Software tools allow for precise display of density maps across 
these volumes, direct measurements of size of abnormalities and analysis of contrast 
enhancement patterns in the presence of iodinated contrast agents. This imaging 
technique is both versatile, easily available and is therefore applied frequently in 
clinical settings. The caveat is that density measurements may be affected by different 
CT reconstruction methods, the protocol applied and the use of intravenous contrast 
agents. Standardisation can be achieved, but requires highly dedicated quality 
assurance. 
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Magnetic resonance imaging (MRI) is a highly versatile method, whereby atoms are 
excited through radiofrequency waves applied in a high magnetic field, leading to a 
change in the alignment of target atoms (usually protons). As the atoms return to their 
resting state, a radiofrequency signal is sent out, which is detected by the system and 
through a mathematical conversion, this can be displayed as an image. Tissues of the 
evaluated body part have different contents of protons, and the signal intensity varies 
accordingly. This technique is highly versatile, may be applied with or without 
contrast agents (e.g. Gadolinium or inhaled hyperpolarised noble gases), and give 
greater detail of tissue characteristics than CT (but generally at slightly lower 
resolution). A potential area of concern is that signal intensity is dependent on many 
parameters, including field strength and chosen sequences. Therefore, standardisation 
is more difficult to achieve that with CT, and requires standardisation of the 
sequences employed. 
 
Positron emission tomography (PET) relies on the injection of radioactive tracers, 
which mimic a normal metabolic pathway in the body. The most commonly used 
compound, 18F fluoro-deoxy-glucose (18F-FDG) is a glucose analog that is taken up 
by cells and starts the Krebs cycle. However, once converted to 18F-FDG-phosphate, 
the next step of the cycle is unable to take place and the substrate is trapped in the 
cell. Cells with increased glucose uptake, such as cancer cells or at sites of 
inflammation, will demonstrate higher radioactivity, which can be measured by 
gamma cameras capable of picking up high energy (511 keV) photons, which are the 
result of the annihilation reaction between protons and electrons. PET is now almost 
always combined with a cross-sectional imaging technique, such as CT or MRI, for 
direct correlation with anatomical structures, as this allows more precise localisation 
of the increased uptake of radiotracer. The technique was traditionally reserved for 
oncology, but, in combination with development  of more targeted radiotracers, it is 
increasingly applied in areas such as cardiovascular diseases, cerebral diseases and for 
evaluation of cellular activity in transplantation for instance. With appropriate quality 
assurance, it is possible to measure absolute radiation values in relation to body mass 
and injected radiotracer, which allows for standardisation of the technique. 
 
Why is there such a focus on developing imaging biomarkers? 
 
Clinical trials have traditionally relied on outcome measures, including symptomatic 
scales, morbidity and mortality rates during the follow-up period after an intervention. 
There are several drawbacks to such an approach, most importantly the number 
needed to treat in order to demonstrate statistically significant differences between 
treatment arms, and the time it takes to perform sufficient follow-up to capture these 
clinical endpoints.[6] 
The cost of developing new drugs has risen astronomically over the past decades. A 
recent report, evaluating the development of 106 new drugs by 10 pharmaceutical 
companies, calculated the total costs from beginning to market approval, to be in the 
range of $2.5 billion in 2013, which is expected to rise to $2.8 billion when 
incorporating post-approval vigilance and follow-up costs. [7] These cost issues have 
led to a number of measures to try and contain them, including joining up efforts of 
drug developments by companies, pre-trial testing with go-no decisions being pushed 
forward, better screening of patients who may benefit from new treatments (targeting) 
and the identification of the need for surrogate measurements of effectiveness. 
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Imaging has captured the attention of regulatory authorities, such as the FDA [8] with 
other initiatives such as the NIH Roadmap [9], the Clinical Trials Transformation 
Initiative[10], the RSNA’s Quantitative Imaging Biomarkers Alliance [11] and the 
European Radiology Society’s Imaging Biomarkers Alliance [12]. They all have in 
common the wish and commitment to develop, qualify and validate imaging 
biomarkers to allow for better utility of imaging in clinical trials. 
 
 
 
How do we qualify and validate imaging biomarkers? 
 
Imaging biomarker qualification and validation is a multi-step process, requiring a 
number of important milestones.[13] Every step is a process which takes up several 
years, and the method may fail anywhere along the line of development. 
Before an imaging method can be considered as a biomarker, it is vital that the 
method is standardised such that it can be applied routinely at any site which wishes 
to introduce it. There is a need for greater standardisation, as both scanner 
manufacturers, individual preferences and patient handling can all affect the imaging 
parameters being studied. This is particularly true for the more advanced imaging 
studies, and it is a major focus of a number of collaborations, largely under guidance 
from the main professional organisations mentioned above. Once a standardised 
protocol has been achieved, the actual qualification of a biomarker can commence. 
 
First, the imaging biomarker must be demonstrated as closely linked to the presence 
(or absence) of the target disease. This usually requires observational studies, 
whereby the imaging biomarkers is correlated to disease presence, extent of disease 
and prognostic value compared to existing methodologies, including clinical 
assessment using standard diagnostic techniques as well as longer-term outcome. This 
process will generate sensitivity and specificity of the diagnostic test. 
Second, as with any diagnostic test, the biomarker requires to be accurate and 
reproducible in both short term and long term measurements. This process should 
start as soon as there is a suggestion that there is a correlation (step 1), and requires 
the application of repeated measurements during a short period of time in patients 
with and without the disease process (immediate and longer reproducibility), multiple 
assessments by several observers (intra- and interobserver varability) and the 
correlation with the actual disease process severity. 
Lastly, any changes measured over time need to be directly related to the changes of 
the target condition. This will require longer-term repeated testing in correlation with 
standard measurements of disease status (e.g. clinical status) with follow-up over 
several years. 
As shown, the qualification is quite a long and arduous process, hence the working 
together of many scientists and organisations is required to pool resources 
appropriately. It is not surprising, therefore, that this process takes many years and 
only now are we starting to see results, having started this work over a decade ago. 
 
The validation of a qualified imaging biomarker is the final step in this process. 
Initially, the evidence built up during the course of the qualification process will allow 
a consensus to be formed among the scientific community that the test is likely to be 
fit for purpose as a biomarker. Subsequently, the efficacy of the biomarker to 
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demonstrate treatment effects that are not seen in non-treated controls, while a 
comparison with routine standards, such as clinical outcome is sought. 
Regulatory authorities, including the FDA and MHRA, are able to collate the 
evidence of a proposed (imaging) biomarker and determine whether the test is 
acceptable as a surrogate endpoint for a clinical trial. These bodies have clearly 
indicated their ascent to the incorporation of surrogate end points for clinical trials, 
provided these end points have been adequately developed and validated. [13] Thus, if 
there is a positive outcome on a surrogate endpoint, this would be regarded as a 
positive result towards market approval for the new treatment.  
 
Examples of clinical approaches to the use of imaging biomarkers 
 
There are many clinical areas where imaging biomarkers are effectively in use, 
particularly in oncologic staging and treatment response assessment. These methods 
are reasonably well established, and offer direct management direction for clinicians 
based on imaging findings (staging) or based on pre and post therapy changes in terms 
of tumour size or change in metabolic activity using PET imaging. In other areas, 
imaging biomarkers are being used as inclusion/exclusion criteria for clinical trials 
where new therapies are being tested that have a known metabolic point of interaction 
(e.g. amyloid plaque PET imaging in qualification of patients for new Alzheimer’s 
disease drugs or bone mineral density assessment for exclusion of patients with 
osteoporosis in drugs that can negatively influence bone mass). It is not possible to 
give an overview of every imaging-based biomarker being tested or available at 
present. Therefore, two areas of interest will be highlighted, where imaging-based 
biomarkers are at the cusp of routine clinical application (emphysema) or are in an 
advanced state of development (aortic valve stenosis). 
 
The use of imaging biomarkers for lung diseases has been piloted for some time. The 
problems encountered largely evolved around standardisation of CT scanner systems, 
but with appropriate quality control and setting the protocols, it is feasible to 
determine some significant phenotypes, which can be used longitudinally to study the 
potential effects of new treatments. Thus, CT-based quantification of emphysema 
both correlates with pulmonary function and mechanics, but additionally offers 
further insights into the phenotypical distribution and extent of disease. [14] 
One of the first attempts demonstrating the feasibility of an imaging-based biomarker 
was made for a large trial evaluating the utility of lung volume reduction surgery in 
patients with severe emphysema, where CT based density distribution was capable of 
predicting outcomes directly. [15] Subsequent imaging analysis further highlighted 
the extent of the correlation between CT quantified findings and the outcomes in the 
surgical and control arms of this large study. [16] This work is now continuing with 
the advent of interventional bronchoscopic methods for lung volume reduction 
surgery, where CT is both used as a tool to determine patient eligibility for the 
procedure and for the planning and assessment of treatment response. [17] 
A longitudinal observational cohort study used CT as a way to determine the extent of 
emphysema, as well as the change over time. [18] Lung density at baseline was 
influenced by a number of variables, including age, sex, body-mass index, current 
smoking status and smoking history, and severity of airflow limitation. Importantly, 
the study could measure annual lung function decline as quantified by CT lung 
density at rates of -1.13 g/L, but with variability due to sex and smoking status. [18] 
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Thus, the CT measurements gave a clearer indication of changes over a one-year 
period compared to pulmonary function tests.  
The COPDGene study enrolled a large cohort of patients (10,000) in multiple centres 
in the USA, who were screened for obstructive outflow disease including genetic 
assessment and the application of CT. [19] The CT protocol was centrally set-up with 
quality assurance rigorously applied. An analysis of 9,313 subject CT scans 
demonstrated a clear quantifiable pattern of low-attenuation findings on CT. [20] 
Additionally, measures of mild emphysema in smokers with preserved lung function 
could be demonstrated as quantifiable low-attenuation changes on CT, allowing for 
earlier diagnosis. [20] 
Subsequent analysis of 10,192 smokers in the COPDGene study demonstrated the 
ability of CT to identify patients with varying degrees of emphysema, as well as the 
presence or absence of airways disease. [21] This enabled identification of four 
subgroups of smokers that were closely associated with clinical characteristics of 
COPD and known COPD-associated genetic variants. [21] 
A third large cohort study, SPIROMICS, deserves mention, as it is closely monitoring 
various serum and plasma biomarkers in combination with CT in 3,200 participants. 
[22] A sub-study evaluated airway measurements in a total of 1,559 subjects, and 
demonstrated that airway walls are thinner and lumen size is smaller in patients with 
COPD compared to controls, and this closely correlated with pulmonary function 
tests. [22] Thus, the study confirmed the findings in the COPDGene study, which 
gave similar findings. [23] 
Overall, where lung imaging is concerned, it is clear that CT-based measures are 
essentially ready to be used as biomarkers. Several measurements are available, 
depending on the specific study questions, and it is vital to ensure protocols are 
appropriately chosen and quality assurance is maintained. The software tools are now 
available for incorporation into routine workstations. This last piece of the puzzle will 
allow more seamless performance of pulmonary CT investigations, which will include 
reporting of quantitative measures of emphysema and airways as part of the standard 
clinical report. Only with this type of workflow can imaging-based biomarkers make 
a difference in clinical practice. 
 
Another area where imaging biomarkers are actively being developed is in cardiac 
applications. Traditionally, invasive cardiac catherization in combination with 
echocardiography and nuclear medicine studies have evaluated the presence of 
coronary artery stenosis, perfusion changes and heart valves. More recently, work has 
been ongoing to delve deeper in the mechanism of aortic valve stenosis and coronary 
atherosclerosis using 18F-sodiumfluoride PET imaging.  
Initial work focused on demonstrating the direct link between the 18F NaF uptake in 
the areas of aortic valve and the histological correlation with the calcific process. [24] 
Subsequently, during a follow-up study of these subjects, it was demonstrated that the 
extent of radiotracer uptake directly correlated with the increase in calcific aortic 
valve disease and functional decline. [25, 26] This work suggests that the detection of 
this process can be achieved much earlier using 18F-NaF PET imaging compared to 
either CT or echocardiographic measurements, and the application of this imaging 
biomarker will likely affect management as the uptake is directly correlated with 
progression of disease. 
In parallel with this work, it was noticed that some patients with aortic valve 
pathology had uptake in coronary arteries. A subsequent study demonstrated that 18F-
NaF PET imaging is correlated with acute myocardial events, and it was postulated 
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that uptake is a reflection of vulnerable plaque, which would be a more accurate and 
important parameter to predict acute coronary artery events than simple angiographic 
methods (which are focussed on level of stenosis). [27] Another study in 40 patients 
with myocardial infarction and 40 patients with stable angina evaluated the role of 
18F-fluorodeoxyglucose uptake in the aorta. [28] This study demonstrated a direct 
correlation between the extent of radiotracer uptake in the aorta and early recurrent 
myocardial infarction, likely due to systemic atherosclerotic inflammatory 
exacerbation and plaque destabilisation. [29] These studies similarly could alter future 
disease management, potentially leading to better identification of active disease and 
the area of plaque most at risk for developing acute myocardial events. In particular, 
more targeted approaches to plaque stabilisation as well as the ability to monitor 
changes over time, will allow development of dedicated new therapies. Further 
studies in this field are ongoing, focused on short and long-term reproducibility and 
long-term follow-up of patients to assess disease progression or modification and 
clinical outcomes in relation to the imaging test. 
 
 
Future perspective 
 
It is highly likely that imaging biomarkers will continue to develop into clinical tools, 
enabling precision and personalised medicine to thrive. Some novel imaging 
biomarkers are now making their inroads into routine clinical practice, others are 
under development, while yet others have hurdles to take (although these are not 
unsurmountable). It will be vital to continue the rigorous process outlined, as this will 
be the only way that regulatory authorities will be able to safely accept these imaging 
biomarkers to be used in routine clinical practice. 
Ultimately, the aim of imaging biomarkers will be a challenge to the training of 
radiologists, who will need to address workflow and reporting changes that are 
required for imaging biomarkers to gain full impact for clinical management of 
patients. It will no longer be sufficient to just describe the findings. They will require 
more precise description in quantitative terms, actual changes over time and 
combination of quantitative imaging findings in relation to prognosis. Imaging 
biomarkers will be used in a variety of ways, some for patient selection, others for 
patient exclusion. This will need to be anticipated by the radiologists as clinicians 
increasingly rely on imaging to provide answers to clinical management questions. 
 Training the radiologists of the future to deal with the increased demand and 
changing reporting requirements is a challenge that will need to be addressed in this 
context. 
 
 
Conclusions 
Imaging biomarkers are already reality, but will continue to be developed to allow for 
more precise assessment of disease, indication for different therapeutic options and 
measure therapy response. This is what will drive individualised patient care 
pathways, where imaging biomarkers will be a core tool, which will have a major 
impact on health economics as a result. The end result will be more appropriate 
treatment of patients at reduced overall costs in terms of both (avoidable) 
complications and overall healthcare costs.  
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The challenges of developing imaging biomarkers and to train the radiologists of the 
future go hand-in-hand, but the rewards are improved patient care while maintaining 
affordability. That is a result worth investing in. 
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Executive summary 
 
• Imaging biomarkers are of interest in order to serve as surrogate endpoints in 
clinical trials, as they can lead to a reduction of sample size due to earlier 
measurement of treatment effects, thus reducing the overall time from start of 
the clinical trial to end point. 
• Imaging biomarkers need to be developed using quite strict qualification and 
validation methodologies, as only this approach will allow useful and 
trustworthy imaging biomarkers to be acceptable for clinical practice. 
• Imaging biomarkers are increasingly making their way into clinical routine 
applications on the back of their efficacy in clinical trials, allowing for 
assessment of disease extent, phenotyping of diseases with multiple genetic 
underlying pathophysiology and response to therapy. 
• Imaging biomarkers have a broad potential, and will likely deliver on the 
approaches to more individualised treatments due to greater targeted 
assessments of suitability.  
• It is important to train radiologists into the utility of imaging biomarkers and 
to develop integrated workflow systems to allow for reporting of quantifiable 
data as part of the routine clinical report. 
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Abstract 
 
Multimodality medical imaging offers a key role in disease diagnosis, while providing 
accurate staging and defining disease extent in many instances. Recent developments 
are increasingly leading to quantitative assessment of medical images, allowing both 
definition of disease extent, giving insight into the phenotypes of diseases and 
offering capabilities of monitoring response to therapy. Combined with other tools, 
such as genetic profiling, this is a powerful way of improving diagnosis and treatment 
of patients, enabling a personalised approach to delivering healthcare. It is highly 
likely that software tools will become integrated into the routine workflow of 
radiology reports. This special report describes some of the crucial areas where 
applications are being introduced and speculate on the potential impact on radiologists 
and clinicians. 
 
Keywords: Radiology, Imaging, Biomarkers, Computed Tomography, Magnetic 
Resonance Imaging, Positron Emission Tomography, Therapy Assessment, 
Quantification, Emphysema, Aortic Valve Stenosis 
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Background of imaging biomarkers 
 
Radiologic imaging has made a huge impact in the overall management of patients, 
allowing rapid and accurate diagnosis for almost any disease on the planetmany 
diseases in one way or another. The range of imaging includes anything from 
ultrasound to plain film radiography and more complex procedures with or without 
the need for ionising radiation. However, in spite of using imaging as a diagnostic 
test, it takes more work to develop an imaging-based biomarker. 
 
An imaging biomarker is a biologic feature or characteristic, that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic 
processes or biological responses to a therapeutic intervention, detectable in an 
image.[1,2] In medicine, an imaging biomarker is a feature of an image relevant to a 
patient's diagnosis. As such, it has been postulated that imaging biomarkers can be 
used as a surrogate to predict utcome and to monitor disease response, thus replacing 
traditional methods such as clinical outcomes (e.g. recurrent disease or death). 
Surrogate biomarkers are thought to assess treatment effects more quickly, thus 
enabling more rapid determination and potential to change patient management.  
 
Although this all sounds relatively new, imaging has been used for many decades as 
an aid to diagnosis, to evaluate extent of disease and to help demonstrate efficacy of 
treatment. Initially this was done using plain radiography methods, and even today 
plain radiographs are commonly used for assessment and classification of spinal and 
other fractures and for follow-up of known lung nodules for instance. With and with 
the advent of advanced imaging methods, such as Computed Tomography (CT), 
Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET), there 
is now increasing clarity in images that enable quantification in real terms, which in 
turn allows for more precise diagnosis and assessment. This is a key component to the 
planning of  “Precision Medicine”, as  improving the phenotype description in the 
context of genetic testing is a very powerful method to indicate likely success of 
newly developed molecular targeted treatments. Thus, it becomes possible to relate 
images to anything from normal biological patterns up to pathophysiological findings 
and measurements of treatment effectiveness. Good examples of this type of imaging 
biomarker are the assessment of chemotherapy effects in cancer treatment (RECIST 
criteria) [3] and also the PET response in patients following treatment of head-neck 
cancer [4] and staging and therapy assessment of lymphoma [5]. 
 
Summary of the main advanced imaging methods 
Computed tomography (CT) is a method of ionising radiation transmission and 
measures density differences of the tissues. The method allows for a three-
dimensional assessment of the targeted volume of the body, and displays are now 
used which depict isovolumetric volumes of tissue (voxel), which can be probed in all 
three dimensions. Software tools allow for precise display of density maps across 
these volumes, direct measurements of size of abnormalities and analysis of contrast 
enhancement patterns in the presence of iodinated contrast agents. This imaging 
technique is both versatile, easily available and is therefore applied frequently in 
clinical settings. The caveat is that density measurements may be affected by different 
CT reconstruction methods, the protocol applied and the use of intravenous contrast 
agents. Standardisation can be achieved, but requires highly dedicated quality 
assurance. 
Formatted: Font: Bold, Underline
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Magnetic resonance imaging (MRI) is a highly versatile method, whereby atoms are 
excited through radiofrequency waves applied in a high magnetic field, leading to a 
change in the alignment of target atoms (usually protons). As the atoms return to their 
resting state, a radiofrequency signal is sent out, which is detected by the system and 
through a mathematical conversion, this can be displayed as an image. Tissues of the 
evaluated body part have different contents of protons, and the signal intensity varies 
accordingly. This technique is highly versatile, may be applied with or without 
contrast agents (e.g. Gadolinium or inhaled hyperpolarised noble gases), and give 
greater detail of tissue characteristics than CT (but generally at slightly lower 
resolution). A potential area of concern is that signal intensity is dependent on many 
parameters, including field strength and chosen sequences. Therefore, standardisation 
is more difficult to achieve that with CT, and requires standardisation of the 
sequences employed. 
 
Positron emission tomography (PET) relies on the injection of radioactive tracers, 
which mimic a normal metabolic pathway in the body. The most commonly used 
compound, 18F fluoro-deoxy-glucose (18F-FDG) is a glucose analog that is taken up 
by cells and starts the Krebs cycle. However, once converted to 18F-FDG-phosphate, 
the next step of the cycle is unable to take place and the substrate is trapped in the 
cell. Cells with increased glucose uptake, such as cancer cells or at sites of 
inflammation, will demonstrate higher radioactivity, which can be measured by 
gamma cameras capable of picking up high energy (511 keV) photons, which are the 
result of the annihilation reaction between protons and electrons. PET is now almost 
always combined with a cross-sectional imaging technique, such as CT or MRI, for 
direct correlation with anatomical structures, as this allows more precise localisation 
of the increased uptake of radiotracer. The technique was traditionally reserved for 
oncology, but, in combination with development  of more targeted radiotracers, it is 
increasingly applied in areas such as cardiovascular diseases, cerebral diseases and for 
evaluation of cellular activity in transplantation for instance. With appropriate quality 
assurance, it is possible to measure absolute radiation values in relation to body mass 
and injected radiotracer, which allows for standardisation of the technique. 
 
Why is there such a focus on developing imaging biomarkers? 
 
Clinical trials have traditionally relied on outcome measures, including symptomatic 
scales, morbidity and mortality rates during the follow-up period after an intervention. 
There are several drawbacks to such an approach, most importantly the number 
needed to treat in order to demonstrate statistically significant differences between 
treatment arms, and the time it takes to perform sufficient follow-up to capture these 
clinical endpoints.[6] 
The cost of developing new drugs has risen astronomically over the past decades. A 
recent report, evaluating the development of 106 new drugs by 10 pharmaceutical 
companies, calculated the total costs from beginning to market approval, to be in the 
range of $2.5 billion in 2013, which is expected to rise to $2.8 billion when 
incorporating post-approval vigilance and follow-up costs. [7] These cost issues have 
led to a number of measures to try and contain them, including joining up efforts of 
drug developments by companies, pre-trial testing with go-no decisions being pushed 
forward, better screening of patients who may benefit from new treatments (targeting) 
and the identification of the need for surrogate measurements of effectiveness. 
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Imaging has captured the attention of regulatory authorities, such as the FDA [8] with 
other initiatives such as the NIH Roadmap [9], the Clinical Trials Transformation 
Initiative[10], the RSNA’s Quantitative Imaging Biomarkers Alliance [11] and the 
European Radiology Society’s Imaging Biomarkers Alliance [12]. They all have in 
common the wish and commitment to develop, qualify and validate imaging 
biomarkers to allow for better utility of imaging in clinical trials. 
 
 
 
How do we qualify and validate imaging biomarkers? 
 
Imaging biomarker qualification and validation is a multi-step process, requiring a 
number of important milestones.[13] Every step is a process which takes up several 
years, and the method may fail anywhere along the line of development. 
Before an imaging method can be considered as a biomarker, it is vital that the 
method is standardised such that it can be applied routinely at any site which wishes 
to introduce it. There is a need for greater standardisation, as both scanner 
manufacturers, individual preferences and patient handling can all affect the imaging 
parameters being studied. This is particularly true for the more advanced imaging 
studies, and it is a major focus of a number of collaborations, largely under guidance 
from the main professional organisations mentioned above. Once a standardised 
protocol has been achieved, the actual qualification of a biomarker can commence. 
 
First, the imaging biomarker must be demonstrated as closely linked to the presence 
(or absence) of the target disease. This usually requires observational studies, 
whereby the imaging biomarkers is correlated to diseas  presence, extent of disease 
and prognostic value compared to existing methodologies, including clinical 
assessment using standard diagnostic techniques as well as longer-term outcome. This 
process will generate sensitivity and specificity of the diagnostic test. 
Second, as with any diagnostic test, the biomarker requires to be accurate and 
reproducible in both short term and long term measurements. This process should 
start as soon as there is a suggestion that there is a correlation (step 1), and requires 
the application of repeated measurements during a short period of time in patients 
with and without the disease process (immediate and longer reproducibility), multiple 
assessments by several observers (intra- and interobserver varability) and the 
correlation with the actual disease process severity. 
Lastly, any changes measured over time need to be directly related to the changes of 
the target condition. This will require longer-term repeated testing in correlation with 
standard measurements of disease status (e.g. clinical status) with follow-up over 
several years. 
As shown, thThe qualification is quite a long and arduous process, hence the working 
together of many scientists and organisations is required to pool resources 
appropriatelyas mentioned above. There are multiple steps required to demonstrate 
the necessary robustness of the imaging test, followed by testing in clinical studies to 
evaluate the true value in comparison with routine outcome measures. It is not 
surprising, Ttherefore, that this process takes many years and only now are we 
starting to see results, having started this work over a decade ago. 
 
The validation of a qualified imaging biomarker is the final step in this process. 
Initially, the evidence built up during the course of the qualification process will allow 
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a consensus to be formed among the scientific community that the test is likely to be 
fit for purpose as a biomarker. Subsequently, the efficacy of the biomarker to 
demonstrate treatment effects that are not seen in non-treated controls, while a 
comparison with routine standards, such as clinical outcome is sought. 
Regulatory authorities, including the FDA and MHRA, are able to collate the 
evidence of a proposed (imaging) biomarker and determine whether the test is 
acceptable as a surrogate endpoint for a clinical trial. These bodies have clearly 
indicated their ascent to the incorporation of surrogate end points for clinical trials, 
provided these end points have been adequately developed and validated. [13] Thus, if 
there is a positive outcome on a surrogate endpoint, this would be regarded as a 
positive result towards market approval for the new treatment.  
 
Examples of clinical approaches to the use of imaging biomarkers 
 
There are many clinical areas where imaging biomarkers are effectively in use, 
particularly in oncologic staging and treatment response assessment. These methods 
are reasonably well established, and offer direct management direction for clinicians 
based on imaging findings (staging) or based on pre and post therapy changes in terms 
of tumour size or change in metabolic activity using PET imaging. In other areas, 
imaging biomarkers are being used as inclusion/exclusion criteria for clinical trials 
where new therapies are being tested that have a known metabolic point of interaction 
(e.g. amyloid plaque PET imaging in qualification of patients for new Alzheimer’s 
disease drugs or bone mineral density assessment for exclusion of patients with 
osteoporosis in drugs that can negatively influence bone mass). It is not possible to 
give an overview of every imaging-based biomarker being tested or available at 
present. Therefore, two areas of interest will be highlighted, where imaging-based 
biomarkers are at the cusp of routine clinical application (emphysema) or are in an 
advanced state of development (aortic valve stenosis). 
 
The use of imaging biomarkers for lung diseases has been piloted for some time. The 
problems encountered largely evolved around standardisation of CT scanner systems, 
but with appropriate quality control and setting the protocols, it is feasible to 
determine some significant phenotypes, which can be used longitudinally to study the 
potential effects of new treatments. Thus, CT-based quantification of emphysema 
both correlates with pulmonary function and mechanics, but additionally offers 
further insights into the phenotypical distribution and extent of disease. [14] 
One of the first attempts demonstrating the feasibility of an imaging-based biomarker 
was made for a large trial evaluating the utility of lung volume reduction surgery in 
patients with severe emphysema, where CT based density distribution was capable of 
predicting outcomes directly. [15] Subsequent imaging analysis further highlighted 
the extent of the correlation between CT quantified findings and the outcomes in the 
surgical and control arms of this large study. [16] This work is now continuing with 
the advent of interventional bronchoscopic methods for lung volume reduction 
surgery, where CT is both used as a tool to determine patient eligibility for the 
procedure and for the planning and assessment of treatment response. [17] 
A longitudinal observational cohort study used CT as a way to determine the extent of 
emphysema, as well as the change over time. [18] Lung density at baseline was 
influenced by a number of variables, including age, sex, body-mass index, current 
smoking status and smoking history, and severity of airflow limitation. Importantly, 
the study could measure annual lung function decline as quantified by CT lung 
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density at rates of -1.13 g/L, but with variability due to sex and smoking status. [18] 
Thus, the CT measurements gave a clearer indication of changes over a one-year 
period compared to pulmonary function tests.  
The COPDGene study enrolled a large cohort of patients (10,000) in multiple centres 
in the USA, who were screened for obstructive outflow disease including genetic 
assessment and the application of CT. [19] The CT protocol was centrally set-up with 
quality assurance rigorously applied. An analysis of 9,313 subject CT scans 
demonstrated a clear quantifiable pattern of low-attenuation findings on CT. [20] 
Additionally, measures of mild emphysema in smokers with preserved lung function 
could be demonstrated as quantifiable low-attenuation changes on CT, allowing for 
earlier diagnosis. [20] 
Subsequent analysis of 10,192 smokers in the COPDGene study demonstrated the 
ability of CT to identify patients with varying degrees of emphysema, as well as the 
presence or absence of airways disease. [21] This enabled identification of four 
subgroups of smokers that were closely associated with clinical characteristics of 
COPD and known COPD-associated genetic variants. [21] 
A third large cohort study, SPIROMICS, deserves mention, as it is closely monitoring 
various serum and plasma biomarkers in combination with CT in 3,200 participants. 
[22] A sub-study evaluated airway measurements in a total of 1,559 subjects, and 
demonstrated that airway walls are thinner and lumen size is smaller in patients with 
COPD compared to controls, and this closely correlated with pulmonary function 
tests. [22] Thus, the study confirmed the findings in the COPDGene study, which 
gave similar findings. [23] 
Overall, where lung imaging is concerned, it is clear that CT-based measures are 
essentially ready to be used as biomarkers. Several measurements are available, 
depending on the specific study questions, and it is vital to ensure protocols are 
appropriately chosen and quality assurance is maintained. The software tools are now 
available for incorporation into routine workstations. This last piece of the puzzle will 
allow more seamless performance of pulmonary CT investigations, which will include 
reporting of quantitative measures of emphysema and airways as part of the standard 
clinical report. Only with this type of workflow can imaging-based biomarkers make 
a difference in clinical practice. 
 
Another area where imaging biomarkers are actively being developed is i  cardiac 
applications. Traditionally, invasive cardiac catherization in combination with 
echocardiography and nuclear medicine studies have evaluated the presence of 
coronary artery stenosis, perfusion changes and heart valves. More recently, work has 
been ongoing to delve deeper in the mechanism of aortic valve stenosis coronary 
atherosclerosis and coronary atherosclerosis aortic valve stenosis using 18F-
sodiumfluoride PET imaging.  
Initial work focused on demonstrating the direct link between the 18F NaF uptake in 
the areas of aortic valve and the histological correlation with the calcific process. [24] 
Subsequently, during a follow-up study of these subjects, it was demonstrated that the 
extent of radiotracer uptake directly correlated with the increase in calcific aortic 
valve disease and functional decline. [25, 26] This work suggests that the detection of 
this process can be achieved much earlier using 18F-NaF PET imaging compared to 
either CT or echocardiographic measurements, and the application of this imaging 
biomarker will likely affect management as the uptake is directly correlated with 
progression of disease. 
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In parallel with this work, it was noticed that some patients with aortic valve 
pathology had uptake in coronary arteries. A subsequent study demonstrated that 18F-
NaF PET imaging is correlated with acute myocardial events, and it was postulated 
that uptake is a reflection oflikely detects vulnerable plaque, which would be a more 
accurately and important parameter to predict acute coronary artery events  than 
simple angiographic methods (which are focussed on level of stenosis). [27] Another 
study in 40 patients with myocardial infarction and 40 patients with stable angina 
evaluated the role of 18F-fluorodeoxyglucose uptake in the aorta. [28] This study 
demonstrated a direct correlation between the extent of radiotracer uptake in the aorta 
and early recurrent myocardial infarction, likely due to systemic atherosclerotic 
inflammatory exacerbation and plaque destabilisation. [29] These studies similarly 
could alter future disease management, potentially leading to better identification of 
active disease and the area of plaque most at risk for developing acute myocardial 
events. In particular, more targeted approaches to plaque stabilisation as well as the 
ability to monitor changes over time, will allow development of dedicated new 
therapies. Further studies in this field are ongoing, focused on short and long-term 
reproducibility and long-term follow-up of patients to assess disease progression or 
modification and clinical outcomes in relation to the imaging test. 
 
 
Future perspective 
 
It is highly likely that imaging biomarkers will continue to develop into clinical tools, 
enabling precision and personalised medicine to thrive. Some novel imaging 
biomarkers are now making their inroads into routine clinical practice, others are 
under development, while yet others have hurdles to take (although these are not 
unsurmountable). It will be vital to continue the rigorous process outlined, as this will 
be the only way that regulatory authorities will be able to safely accept these imaging 
biomarkers to be used in routine clinical practice. 
Ultimately, the aim of imaging biomarkers will be a challenge to the training of 
radiologists, who will need to address workflow and reporting changes that are 
required for imaging biomarkers to gain full impact for clinical management of 
patients. It will no longer be sufficient to just describe the findings. They will require 
more precise description in quantitative terms, actual changes over time and 
combination of quantitative imaging findings in relation to prognosis. Imaging 
biomarkers will be used in a variety of ways, some for patient selection, others for 
patient exclusion. This will need to be anticipated by the radiologists as clinicians 
increasingly rely on imaging to provide answers to clinical management questions. 
have studies that demonstrate the robustness of quantitative imaging techniques and 
measurements, but as this field progresses, with the incorporation of imaging based 
treatment response assessment into clinical trials, the natural progression is one where 
radiologists will be offering both a morphological/visual assessment together with 
image analytical tools to provide greater insight into the extent of disease, the 
potential selection of patients for (often expensive) specific treatments and the 
ultimate therapeutic effectiveness. Only with this approach, will the additional value 
of diagnostic imaging become apparent. Training the radiologists of the future to deal 
with the increased demand and changing reporting requirements is a challenge that 
will need to be addressed in this context. 
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Conclusions 
Imaging biomarkers are already reality, but will continue to be developed to allow for 
more precise assessment of disease, indication for different therapeutic options and 
measure therapy response. This is what will drive individualised patient care 
pathways, where imaging biomarkers will be a core tool, which will have a major 
impact on health economics as a result. The end result will be more appropriate 
treatment of patients at reduced overall costs in terms of both (avoidable) 
complications and overall healthcare costs.  
The challenges of developing imaging biomarkers and to train the radiologists of the 
future go hand-in-hand, but the rewards are improved patient care while maintaining 
affordability. That is a result worth investing in. 
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Executive summary 
 
• Imaging biomarkers are of interest in order to serve as surrogate endpoints in 
clinical trials, as they can lead to a reduction of sample size due to earlier 
measurement of treatment effects, thus reducing the overall time from start of 
the clinical trial to end point. 
• Imaging biomarkers need to be developed using quite strict qualification and 
validation methodologies, as only this approach will allow useful and 
trustworthy imaging biomarkers to be acceptable for clinical practice. 
• Imaging biomarkers are increasingly making their way into clinical routine 
applications on the back of their efficacy in clinical trials, allowing for 
assessment of disease extent, phenotyping of diseases with multiple genetic 
underlying pathophysiology and response to therapy. 
• Imaging biomarkers have a broad potential, and will likely deliver on the 
approaches to more individualised treatments due to greater targeted 
assessments of suitability.  
• It is important to train radiologists into the utility of imaging biomarkers and 
to develop integrated workflow systems to allow for reporting of quantifiable 
data as part of the routine clinical report. 
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